Compare · NVO vs QTTB
NVO vs QTTB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Q32 Bio Inc. (QTTB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QTTB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 897.9x QTTB ($204.0M).
- Over the past year, NVO is down 45.7% and QTTB is up 550.8% - QTTB leads by 596.5 points.
- QTTB has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for QTTB).
- Company
- Novo Nordisk A/S
- Q32 Bio Inc.
- Price
- $41.01-4.51%
- $12.04-8.09%
- Market cap
- $183.15B
- $204.0M
- 1M return
- -10.44%
- +122.96%
- 1Y return
- -45.66%
- +550.81%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 10
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest QTTB
- New insider Atlas Venture Opportunity Fund Ill, L.P. claimed ownership of 625,000 shares (SEC Form 3)
- SEC Form SCHEDULE 13G filed by Q32 Bio Inc.
- SEC Form SCHEDULE 13G filed by Q32 Bio Inc.
- Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)
- Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.
- Q32 Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Q32 Bio Announces $55 Million Private Placement Financing
- Cantor Fitzgerald initiated coverage on Q32 Bio